Search for dissertations about: "targeted therapies"

Showing result 1 - 5 of 145 swedish dissertations containing the words targeted therapies.

  2. 1. New targeted therapies for malignant neural tumors : From systematic discovery to zebrafish models

    Author : Elin Almstedt; Sven Nelander; Rogier Versteeg; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; neuroblastoma; glioblastoma; data integration; zebrafish models; precision medicine; Oncology; Onkologi; Medical Cell Biology; Medicinsk cellbiologi; Medical Informatics; Medicinsk informatik; Farmakokinetik och läkemedelsterapi; Pharmacokinetics and Drug Therapy; Molekylär medicin; Molecular Medicine;

    Abstract : Cancers in the neural system presents a major health challenge. The most aggressive brain tumor in adults, glioblastoma, has a median survival of 15 months and few therapeutic options. High-risk neuroblastoma, a childhood tumor originating in the sympathetic nervous system, has a 5-year survival under 50%, despite extensive therapy. READ MORE

  4. 2. MYC-driven Medulloblastoma : New Targeted Therapies and Mechanisms of Recurrence

    Author : Anna Borgenvik; Fredrik J. Swartling; Lars-Gunnar Larsson; Sonja Hutter; Pratiti (Mimi) Bandopadhayay; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Medulloblastoma; Pediatric cancer; Recurrence; MYC; MYCN; SOX9; Treatment; Bet bromodomains; Cyclin-dependent kinases; Oncology; Onkologi; Medicinsk vetenskap; Medical Science;

    Abstract : Medulloblastoma is the most common malignant brain tumor of childhood. It arises in the posterior fossa but presents with distinct histological and molecular features. Hence, medulloblastoma is divided into four molecular subgroups, WNT, SHH, Group 3, and Group 4. READ MORE

  5. 3. Mechanisms of Medulloblastoma Dissemination and Novel Targeted Therapies

    Author : Sara Bolin; Fredrik Swartling; Martine F. Roussel; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Medulloblastoma; Recurrence; MYC; SOX9; FBW7; Treatment; BET bromodomains; Cyclin-dependent kinases; Oncology; Onkologi;

    Abstract : Medulloblastomas are the most frequent malignant childhood brain tumors, arising in the posterior fossa of children. The overall 5-year survival is 70%, although children often suffer severe long-term side effects from standard medical care. READ MORE

  6. 4. Studies of New Signal Transduction Modulators in Acute Myeloid Leukemia

    Author : Anna Eriksson; Martin Höglund; Rolf Larsson; Bjørn Tore Gjertsen; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Acute myeloid leukemia; Targeted therapies; Drug development; Tyrosine kinase inhibition; AKN-032; AKN-028; Internmedicin; Internal Medicine;

    Abstract : Acute myeloid leukemia (AML) is a life-threatening malignant disorder with dismal prognosis. AML is characterized by frequent genetic changes involving tyrosine kinases, normally acting as important mediators in many basic cellular processes. READ MORE

  7. 5. Pharmacometrics to improve clinical benefit assessment in oncology

    Author : Emilie Schindler; Lena E Friberg; Mats O Karlsson; Rik de Greef; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; nonlinear mixed effect models; NONMEM; pharmacokinetics; pharmacodynamics; VEGF; SLD; targeted therapies; IRT; FDG-PET; SUVmax; Farmaceutisk vetenskap; Pharmaceutical Science;

    Abstract : The high attrition rate in oncology drug development calls for new approaches that would increase the understanding of drugs’ efficacy and safety profiles. This thesis focuses on the development of pharmacometric models to characterize and quantify the relationships between drug exposure, circulating and imaging biomarkers, adverse effects, overall survival (OS), and patient-reported outcomes (PROs). READ MORE